<DOC>
	<DOCNO>NCT00859833</DOCNO>
	<brief_summary>We test hypothesis single dose Regadenoson produce equivalent degree coronary hyperemia patient widely different body size . This prospective , open-label , comparative trial use MRI measure myocardial perfusion reserve ( ratio myocardial blood flow vasodilator myocardial blood flow rest ) sequential administration coronary vasodilator adenosine regadenoson . Non-invasive MRI measurement rest myocardial blood flow , sequential measurement blood flow adenosine infusion ( weight adjust dose ) blood flow regadenoson infusion ( single , fix dose . Blood flow measurement obtain sequentially sequence subject two hour MRI exam . 32 subject recruit study . The first 2 test protocol . Inclusion criterion : 2 subject initial protocol evaluation , 30 subject body mass index ( BMI ) 18 40 . Exclusions pregnancy , renal dysfunction claustrophobia .</brief_summary>
	<brief_title>Effects Body Mass Index Hyperemic Response Regadenoson</brief_title>
	<detailed_description>Introduction : Regadenoson ( Lexiscan ) currently recommend use target vasodilator myocardial perfusion study available single , fix dose patient . Here propose compare hyperemic response measure MRI subject wide range BMI 18-40 . MRI ideal test compare effect regadenoson patient different body mass index ( BMIs ) . No radiation use multiple perfusion test perform close temporal sequence . Importantly , number researcher show ability obtain quantitative stress rest myocardial blood flow value heart MR imaging . This allow calculation myocardial perfusion reserve ( MPR ) . Flow reserve measurement also do dynamic PET , SPECT . PET disadvantage radiation exposure . Regadenoson may desirable agent use MRI adenosine . Adenosine require use 2 intravenous line , use either specialized , expensive , MRI-compatible infusion pump deliver drug , long lengths tube run pump outside scanner room . Neither solution ideal . Regadenoson require pump start second i.v.. The work would accomplish 2 goal : 1 ) demonstrate feasibility perform quantitative MRI perfusion measurement regadenoson , 2 ) test whether single dose regadenoson produce maximal coronary hyperemia across wide range body size . Study Design : This prospective , open-label , study . The design single group , one arm , 2 intervention compare MPR measure sequentially adenosine regadenoson use MRI . Non-invasive MRI measurement rest flow , flow adenosine stress , flow regadenoson stress obtain sequentially subject single two hour MRI exam . Each drug give order subject . 32 subject recruit study . The first two subject image rest perfusion , order determine optimal acquisition parameter study , use analysis . The main outcome measure MPR agent .</detailed_description>
	<mesh_term>Adenosine</mesh_term>
	<mesh_term>Regadenoson</mesh_term>
	<criteria>BMI 2040 kg/m^2 age 1888 critically ill patient , patient ventilator , patient hypotension , asthmatic , patient whose medical care safety may compromise undergo MRI examination exclude . Patients claustrophobia also exclude . Also , anyone contraindication MRI ( pacemaker , ICD , metal implant ) , pregnant subject , minor , prisoner exclude study . If subject 60 suspicion abnormal kidney function , blood test determine GFR perform prior imaging . Subjects GFR &lt; 30 exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>88 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>adenosine</keyword>
	<keyword>regadenoson</keyword>
	<keyword>adenosine receptor subtypes</keyword>
</DOC>